PL2293819T3 - Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2 - Google Patents

Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2

Info

Publication number
PL2293819T3
PL2293819T3 PL09772265T PL09772265T PL2293819T3 PL 2293819 T3 PL2293819 T3 PL 2293819T3 PL 09772265 T PL09772265 T PL 09772265T PL 09772265 T PL09772265 T PL 09772265T PL 2293819 T3 PL2293819 T3 PL 2293819T3
Authority
PL
Poland
Prior art keywords
her2 receptor
truncated variant
cancers expressing
diagnosing cancers
diagnosing
Prior art date
Application number
PL09772265T
Other languages
English (en)
Inventor
López Joaquín Arribas
Kim Pedersen
Pier-Davide Angellini
Palau Josep Lluis Parra
Sirle Laos
Torres José Baselga
Original Assignee
Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron
Fundacio Privada Inst Catalana De Recerca I Estudis Avancants
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron, Fundacio Privada Inst Catalana De Recerca I Estudis Avancants, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron
Publication of PL2293819T3 publication Critical patent/PL2293819T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09772265T 2008-06-02 2009-06-05 Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2 PL2293819T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
EP09772265.6A EP2293819B1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing a truncated her2 receptor variant
PCT/EP2009/056976 WO2010000565A1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Publications (1)

Publication Number Publication Date
PL2293819T3 true PL2293819T3 (pl) 2015-04-30

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09772265T PL2293819T3 (pl) 2008-06-02 2009-06-05 Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2

Country Status (20)

Country Link
US (1) US8389227B2 (pl)
EP (1) EP2293819B1 (pl)
JP (2) JP5753079B2 (pl)
KR (2) KR20160140974A (pl)
CN (1) CN102202692B (pl)
AU (2) AU2009265921B2 (pl)
BR (1) BRPI0914969A2 (pl)
CA (1) CA2727365A1 (pl)
CY (1) CY1115798T1 (pl)
DK (1) DK2293819T3 (pl)
EA (1) EA025218B1 (pl)
ES (2) ES2342646B1 (pl)
HR (1) HRP20141158T1 (pl)
IL (1) IL209769A (pl)
MX (1) MX2010013419A (pl)
PL (1) PL2293819T3 (pl)
PT (1) PT2293819E (pl)
SI (1) SI2293819T1 (pl)
WO (1) WO2010000565A1 (pl)
ZA (1) ZA201009010B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081649A2 (en) * 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
PT2330131E (pt) * 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
CN109476744B (zh) * 2016-05-12 2023-04-11 新加坡科技研究局 抗erbb-2抗体及其用途
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
BR112022001148A2 (pt) 2019-07-23 2022-03-15 Inst Nat Sante Rech Med Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品
EP4077368A1 (en) * 2019-12-18 2022-10-26 Bracco Imaging SPA Anti-her2 polypeptides derivatives as new diagnostic molecular probes
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
KR20250147080A (ko) * 2024-04-03 2025-10-13 한국원자력의학원 방사성동위원소가 표지된 항-her2 항체-킬레이터 접합체, 이를 포함하는 약학적 조성물 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE69535673D1 (de) 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
DE69725857T2 (de) * 1996-08-14 2004-07-29 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Vektor für polynukleotidimpfstoffe
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
DE60040981D1 (de) 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
EP1653986A4 (en) * 2003-08-01 2007-03-14 Smithkline Beecham Corp TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
ES2637411T3 (es) * 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95

Also Published As

Publication number Publication date
ZA201009010B (en) 2012-03-28
JP5753079B2 (ja) 2015-07-22
ES2528132T3 (es) 2015-02-04
ES2342646B1 (es) 2011-04-26
ES2342646A1 (es) 2010-07-09
EP2293819A1 (en) 2011-03-16
KR20160140974A (ko) 2016-12-07
EA201001874A1 (ru) 2011-08-30
BRPI0914969A2 (pt) 2015-10-20
KR20110031187A (ko) 2011-03-24
KR101785117B1 (ko) 2017-11-07
HK1157658A1 (en) 2012-07-06
HRP20141158T1 (hr) 2015-02-13
WO2010000565A1 (en) 2010-01-07
IL209769A0 (en) 2011-02-28
CN102202692B (zh) 2014-03-12
JP2015214546A (ja) 2015-12-03
AU2015202854A1 (en) 2015-06-18
US20090311262A1 (en) 2009-12-17
CA2727365A1 (en) 2010-01-07
DK2293819T3 (en) 2014-12-08
IL209769A (en) 2016-04-21
EP2293819B1 (en) 2014-09-03
CN102202692A (zh) 2011-09-28
MX2010013419A (es) 2011-08-15
JP2011525175A (ja) 2011-09-15
PT2293819E (pt) 2014-12-09
EA025218B1 (ru) 2016-12-30
US8389227B2 (en) 2013-03-05
CY1115798T1 (el) 2017-01-25
SI2293819T1 (sl) 2015-01-30
AU2009265921B2 (en) 2015-04-02
AU2009265921A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
PL2293819T3 (pl) Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0923359A2 (pt) Anticorpos anti-igf
EP1981902A4 (en) ANTAGONISTS OF NOGO RECEPTORS
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
IL212175B (en) Muc1* antibodies
BRPI1012589A2 (pt) anticorpos bi-específicos anti-erbb-3/anti-c-met
BRPI0917148A2 (pt) anticorpos anti-cd5
DK2059534T3 (da) Gensplejsede anti-il-23p19-antistoffer
PT2406284T (pt) Anticorpos anti-bcma
BR112012008159A2 (pt) moduladores de receptor canabinoide
BRPI1011005A2 (pt) anticorpos anti-epcam
BRPI0922800A2 (pt) anticorpos c-met
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
EP2207803A4 (en) Cd9-specific human antibodies
EP2300828A4 (en) SCREENING SYSTEM FOR ANTIGENS
ZA201103178B (en) Anti-tgf-beta receptor ii antibodies
EP2292752A4 (en) CAPSULE WITHOUT SOLDER
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
BRPI0909633A2 (pt) anticorpos anti-tyrp1
PL2330131T3 (pl) Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
BRPI0912769A2 (pt) anticorpos anti-pirb
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos